Deutsche Bank set a €75.00 ($87.21) target price on Bayer (FRA:BAYN) in a report issued on Thursday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the healthcare company’s stock.
A number of other research analysts also recently issued reports on BAYN. Morgan Stanley set a €86.00 ($100.00) price target on Bayer and gave the company a buy rating in a report on Monday, January 6th. Sanford C. Bernstein set a €90.00 ($104.65) price objective on Bayer and gave the company a buy rating in a research report on Tuesday, January 21st. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the company a buy rating in a research report on Monday, January 20th. Nord/LB set a €64.00 ($74.42) price objective on Bayer and gave the company a neutral rating in a research report on Tuesday, January 21st. Finally, Kepler Capital Markets set a €73.00 ($84.88) price objective on Bayer and gave the company a neutral rating in a research report on Thursday, January 9th. Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of Buy and a consensus target price of €81.89 ($95.22).
Shares of FRA:BAYN traded up €0.07 ($0.08) during midday trading on Thursday, reaching €77.37 ($89.97). 1,591,189 shares of the company’s stock traded hands. Bayer has a one year low of €91.58 ($106.49) and a one year high of €123.82 ($143.98). The stock has a 50 day moving average of €74.71 and a 200 day moving average of €68.47.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: Support Level
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.